logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Advanced cholangiocarcinoma: encouraging response rates with pemigatinib in selected patients

Patients with a rare disease harbouring rare mutations can be identified and successfully treated.